Given the various challenges associated with co-development of companion diagnostics and drug / therapy, drug developers prefer to rely on third-party service providers that offer customized services and advanced technologies
Roots Analysis has announced the addition of “Companion Diagnostics Development Services Market (2nd Edition), 2022-2035” report to its list of offerings.
The growing pipeline of patient-centric targeted therapies has led to a surge in demand for companion diagnostics; these tests are known to improve the success rates of late-stage trials by almost three-fold. The development and approval of these FDA classified high-risk devices requires multidisciplinary expertise and an established network of R&D and production facilities that can be accessed through service providers.
To order this 660+ page report, which features 190+ figures and 260+ tables, please visit
https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html
Over 150 companies claim to offer companion diagnostics development services, globally
Nearly 60% of the aforementioned players are based in North America, followed by the players located in Europe (30%). Further, this segment of the industry is dominated by the presence of mid-sized players (51-200 employees), which represent 40% of the total service providers.
Nearly 15% players claim to act as one-stop shops, offering services, ranging from biomarker discovery and development to manufacturing and commercialization
Most of the service providers (127) provide assay development services, followed by companies (124) offering services for biomarker discovery / identification. Further, NGS is the most popular technique, employed by over 100 service providers.
Over 90 companies are actively involved in the development of companion diagnostics
Nearly 91% of the total tests can detect mutations in a single biomarker. Amongst these, ErbB gene family (HER-2 and EGFR genes), PD-L1 genes, RAS gene family (KRAS and NRAS genes), BRCA gene family (BRCA1 and BRCA2) and BRAF emerged as the key genes which are assessed by majority of the companion diagnostics.
Partnership activity in this domain has increased at a CAGR of ~25%, between 2017 and 2021
Mergers and acquisitions, product development agreements and product development and commercialization agreements account for more than 60% of the total number of deals inked during the given time period. It is worth highlighting that nearly 25% of the total number of deals were signed in 2021. Further, the maximum number (177) of partnerships have been inked for companion diagnostics being developed for the treatment of oncological disorders.
North America is expected to capture ~60% share in the companion diagnostics development services market by 2035
Owing to the high costs associated with the clinical validation of companion diagnostics, a significant proportion (~46%) of service revenues is generated from this step, in 2035. In terms of analytical technique used, service contracts involving NGS are anticipated to contribute to more than 35% of the total service revenues generated in 2035. Further, close to 90% of the total service revenues, in 2035, are generated from companion diagnostics development projects for cancer indications.
To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html
The financial opportunity within the companion diagnostics development services market has been analyzed across the following segments:
The report also features detailed transcripts of discussions (in reverse chronological order) held with the following experts:
The research includes detailed profiles of key players (listed below), each profile features an overview of the company, its financial information (if available), drug portfolio, details on recent developments, and an informed future outlook.
For additional details, please visit
https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html or email sales@rootsanalysis.com
You may also be interested in the following titles:
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.chaudhary@rootsanalysis.com
MEDIA CITATIONS
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES
.png)
